LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 15 of 15: Calculated dose-response metrics. - Dataset (ID:20252)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | GR_AOC |
|---|---|---|
| MDA-MB-231 | CP466722 | 0.0929 |
| MDA-MB-231 | CP724714 | 0.1058 |
| MDA-MB-231 | Crizotinib | 0.4362 |
| MDA-MB-231 | Momelotinib | 0.4516 |
| MDA-MB-231 | Dasatinib | 1.1574 |
| MDA-MB-231 | Dovitinib | 0.4475 |
| MDA-MB-231 | Enzastaurin | -0.0058 |
| MDA-MB-231 | Erlotinib | 0.0781 |
| MDA-MB-231 | Alvocidib | 1.2235 |
| MDA-MB-231 | Foretinib | 0.7433 |
| MDA-MB-231 | Pictilisib | 0.3154 |
| MDA-MB-231 | GDC-0980 | 0.5978 |
| MDA-MB-231 | Gefitinib | -0.0096 |
| MDA-MB-231 | Geldanamycin | 1.0057 |
| MDA-MB-231 | GSK 690693 | 0.0733 |
| MDA-MB-231 | GSK1059615 | 0.3713 |
| MDA-MB-231 | GSK1904529A | 0.0980 |
| MDA-MB-231 | Omipalisib | 0.9317 |
| MDA-MB-231 | GW843682X | 0.6697 |
| MDA-MB-231 | HG-5-113-01 | 0.4873 |
| MDA-MB-231 | HG-5-88-01 | 0.2167 |
| MDA-MB-231 | HG-6-64-01 | 0.5492 |
| MDA-MB-231 | Imatinib | 0.0035 |
| MDA-MB-231 | JNK-9L | 0.7085 |
| MDA-MB-231 | JW-7-24-1 | 0.3625 |